CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement.

Autor:	Ng CT; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.; Department of Cardiology, National Heart Centre Singapore., Gonzalez Bonilla HM; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA., Chang I; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA., Aung MT; Department of Hematology, The University of Kansas Cancer Center, Kansas City, Kansas, USA., Gile JJ; Department of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Pereira NL; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA., Villasboas Bisneto JC; Department of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Johnston PB; Department of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Villarraga HR; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA., Rodriguez-Porcel MG; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA., Lin G; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA., Lin Y; Department of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA., Herrmann J; Department of Cardiovascular Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	JACC. Case reports [JACC Case Rep] 2023 Apr 21; Vol. 15, pp. 101840. Date of Electronic Publication: 2023 Apr 21 (Print Publication: 2023).
DOI:	10.1016/j.jaccas.2023.101840
Abstrakt:	Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life-threatening complications such as ventricular rupture, cardiac tamponade, and circulatory failure. We present a case series of patients with lymphoma and cardiomyopathy or cardiac metastasis managed with chimeric antigen receptor T-cell therapy. ( Level of Difficulty: Advanced. ). Competing Interests: Dr Y. Lin has received consultancy fees from Kite/Gilead, Celgene/BMS, Juno/BMS, bluebird bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Iovance, Takeda, Fosun Kite, and Pfizer. Dr Herrmann has received consultancy fees from Pfizer and is supported by the National Cancer Institute (CA 233610). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu